All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
Lisocabtagene maraleucel (liso-cel; JCAR017) is an investigational anti-CD19 chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ CAR T cells. The administration of liso-cel in the outpatient setting is allowed based on the discretion of the investigator and needs to follow standardized guidelines for safety monitoring and management. Outpatient administration provides multiple advantages, including making CAR T-cell therapy more accessible.1
During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, Carlos Bachier1 presented the results of a study evaluating the safety and efficacy of liso-cel in patients with relapsed/refractory large B-cell lymphoma (LBCL) who were monitored as outpatients at both university and non-university sites in three separate TRANSCEND studies: the phase I NHL-001 (NCT02631044) and the phase II OUTREACH (NCT03744676) and PILOT (NCT03483103) trials.
After lymphodepletion with fludarabine (30 mg/m2) and cyclophosphamide (300 mg/m2) for 3 days, liso-cel was administered at either 50 × 106, 100 × 106, or 150 × 106 CAR T cells for patients recruited on the TRANSCEND NHL-001 study, or at 100 × 106 CAR T cells on the PILOT and OUTREACH studies.
Patients were considered outpatients if they received liso-cel infusion in the outpatient or inpatient setting and if they left the clinic or were discharged from the hospital at the end of the observation period on the day of infusion. Patients were required to receive safety monitoring education, have a caregiver, and stay within a one hour travel time to the site of care for 30 days posttreatment. All study sites had a multidisciplinary CAR T-cell team and standard operating procedures for toxicity management and monitoring.
At data cutoff, 59 patients were treated and/or monitored as outpatients across the three studies (TRANSCEND NHL 001, n = 25; OUTREACH, n = 22; and PILOT, n = 12). Baseline demographics, safety outcomes, and response are reported in Table 1.
Table 1. Patient characteristics, safety outcomes, and response1
CR, complete response; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL3B, follicular lymphoma Grade 3B; HGBCL, high grade B-cell lymphoma; HSCT, hematopoietic stem cell transplant; NE, neurological event; ORR, overall response rate; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; PR, partial response; SD, stable disease; TEAE, treatment-emergent adverse event. |
|||||
|
Outpatients |
Inpatients (n = 273) |
|||
---|---|---|---|---|---|
TRANSCEND NHL 001 (n = 25) |
OUTREACH (n = 22) |
PILOT (n = 12) |
Total (n = 59) |
||
Patient characteristics |
|||||
Median age, years (range) |
60 (24─82) |
65 (50─83) |
72 (58─80) |
63 (24─83) |
64 (18─86) |
≥ 65, n (%) |
7 (28) |
11 (50) |
10 (83) |
28 (47) |
127 (47) |
Histology, n (%) |
|
|
|
|
|
DLBCL not otherwise specified |
14 (56) |
17 (77) |
7 (58) |
38 (64) |
136 (50) |
DLBCL transformed from indolent histologies |
5 (20) |
5 (23) |
0 (0) |
10 (17) |
78 (29) |
HGBCL/PMBCL/FL3B |
6 (24) |
0 (0) |
5 (42) |
11 (19) |
59 (22) |
ECOG PS of 0─1/2 at screening, n (%) |
25 (100)/0 (0) |
22 (100)/0 (0) |
9 (75)/3 (25) |
56 (95)/3 (5) |
263 (96)/10 (4) |
Prior lines of therapy, median (range) |
2 (1─5) |
2 (2─5) |
1 (1─1) |
2 (1─5) |
2 (1─8) |
Prior HSCT, n (%) |
9 (36) |
7 (32) |
0 (0) |
16 (27) |
10 (4) |
Chemotherapy refractory, n (%) |
16 (64) |
16 (73) |
6 (50) |
38 (64) |
184 (67) |
Safety |
|||||
TEAEs Grade 5, n (%) |
0 |
0 |
0 |
0 |
8 (3) |
CRS or NEs, n (%) |
|
|
|
|
|
Any grade |
15 (60) |
10 (45) |
0 (0) |
25 (42) |
124 (45) |
Grade ≥ 3 |
2 (8) |
1 (5) |
0 (0) |
3 (5) |
29 (11) |
CRS, n (%) |
|
|
|
|
|
Any grade |
12 (48) |
9 (41) |
0 (0) |
21 (36) |
111 (41) |
Grade ≥ 3 |
1 (4) |
0 (0) |
0 (0) |
1 (2) |
5 (2) |
NEs, n (%) |
|
|
|
|
|
Any grade |
11 (44) |
6 (27) |
0 (0) |
17 (29) |
75 (27) |
Grade ≥ 3 |
2 (8) |
1 (5) |
0 (0) |
3 (5) |
27 (10) |
Median time to CRS onset, days |
— |
— |
— |
5 |
4 |
Median time to NE onset, days |
— |
— |
— |
8 |
9 |
Median duration of CRS, days |
— |
— |
— |
5 |
5 |
Median duration of NEs, days |
— |
— |
— |
7 |
9 |
Tocilizumab or corticosteroid for CRS, n (%) |
|
|
|
|
|
Tocilizumab only |
0 |
0 |
0 |
0 |
28 (10) |
Tocilizumab and corticosteroid |
1 (4) |
3 (14) |
0 |
4 (7) |
23 (8) |
Corticosteroid only |
2 (8) |
0 |
0 |
2 (3) |
3 (1) |
Corticosteroids for NEs, n (%) |
5 (20) |
2 (9) |
0 |
7 (12) |
42 (15) |
Best overall response, n (%) |
|||||
ORR |
20 (80) |
16 (84) |
11 (92) |
47 (84) |
189 (73) |
CR |
14 (56) |
13 (68) |
7 (58) |
34 (61) |
137 (53) |
PR |
6 (24) |
3 (16) |
4 (33) |
13 (23) |
52 (20) |
SD |
2 (8) |
1 (5) |
0 (0) |
3 (5) |
29 (11) |
PD |
3 (12) |
2 (11) |
1 (8) |
6 (11) |
28 (11) |
Not evaluable |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
10 (4) |
Hospitalization was required for 54% of outpatients, with a median length of stay of six days, and the main reasons for admission were cytokine release syndrome (CRS) and/or neurological events (17 patients) and other adverse events (15 patients). Two patients required treatment in the intensive care unit: one for CRS and one for dehydration.
The safety profile of liso-cel following outpatient administration showed no increase in rates of severe CRS or other adverse events when compared to inpatient administration. These data, together with the similar efficacy rates observed between the outpatient and inpatient settings, support outpatient liso-cel administration for patients with relapsed/refractory LBCL, provided that the proper safety monitoring and standard operating protcols are being followed. Outpatient administration and monitoring of liso-cel continue to be evaluated and further data are expected to further validate these results.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox